We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BioFire Diagnostics

BioFire Diagnostics, a subsidiary of bioMérieux SA, offers easy-to-use clinical molecular diagnostic solutions based ... read more Featured Products: More products

Download Mobile App




Enterovirus D68 Genome Sequenced

By LabMedica International staff writers
Posted on 11 Nov 2014
In recent months, the rare Enterovirus D68 (EV-D68) has spread rapidly across North America and caused severe respiratory illness in young children, with some requiring hospitalization.

Routine laboratory tests cannot identify specific Enterovirus and most hospitals and clinics can only perform tests to determine if a patient has a virus that fits broadly into the Enterovirus/rhinovirus category. More...
As only specialized laboratories can identify the virus, merely 594 cases of EV-D68 infection have been officially confirmed in 43 US states and the District of Columbia.

Scientists at the Washington University School of Medicine (St. Louis, MO, USA) analyzed 14 patient samples testing positive for Enterovirus/rhinovirus. They determined the complete coding sequence of one strain from St. Louis by using high-throughput sequencing of nucleic acid from a clinical sample. To evaluate the sequence diversity in EV-D68 strains circulating in the St. Louis metropolitan area, they also generated partial-genome sequences from eight more EV-D68–positive clinical samples from the immediate area.

Residual material from a subset of nasopharyngeal specimens positive for Enterovirus/rhinovirus that had been tested by the BioFire FilmArray Respiratory Panel (BioFire Diagnostics; Salt Lake City, UT, USA) were selected for high-throughput sequencing. Total nucleic acid was extracted from clinical samples by using NucliSENS easyMAG (bioMérieux; Marcy l'Etoile, France) and used to make dual-indexed sequencing libraries. Enterovirus/rhinovirus sequences were enriched by using a NimbleGen custom sequence capture reagent (Roche/NimbleGen; Madison, WI, USA), which as of February 2014 was selective for all complete Enterovirus and rhinovirus genomes in the GenBank. Sequence data were generated on a HiSeq 2500 (Illumina; San Diego, CA, USA).

Of the 14 patient samples tested, nine were identified as infected with EV-D68 and the remaining five samples were other respiratory viruses. Seven of the nine patients with the EV-D68 strain had severe disease that required admission to the pediatric intensive care unit. The remaining two had moderate symptoms resulting in general hospital admission. Of the five patients with other viruses, three were classified with severe disease. The only two patients discharged home with mild disease did not have the EV-D68 strain.

Gregory A. Storch, MD, a professor of Pediatrics and senior author of the study said, “Having the DNA sequence of this virus enables additional investigative studies. It can be used to create better diagnostic tests. It also may help us understand why this epidemic seems to be producing severe and unusual disease, and why it's spreading more extensively than in the past." The study was published on October 28, 2014, in the journal Emerging Infectious Diseases.

Related Links:

Washington University School of Medicine
BioFire Diagnostics
BioMérieux



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.